Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 62

1.

Structure of the full-length Clostridium difficile toxin B.

Chen P, Lam KH, Liu Z, Mindlin FA, Chen B, Gutierrez CB, Huang L, Zhang Y, Hamza T, Feng H, Matsui T, Bowen ME, Perry K, Jin R.

Nat Struct Mol Biol. 2019 Aug;26(8):712-719. doi: 10.1038/s41594-019-0268-0. Epub 2019 Jul 15.

PMID:
31308519
2.

Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B.

Simeon R, Jiang M, Chamoun-Emanuelli AM, Yu H, Zhang Y, Meng R, Peng Z, Jakana J, Zhang J, Feng H, Chen Z.

PLoS Biol. 2019 Jun 24;17(6):e3000311. doi: 10.1371/journal.pbio.3000311. eCollection 2019 Jun.

3.

Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota.

Tam J, Hamza T, Ma B, Chen K, Beilhartz GL, Ravel J, Feng H, Melnyk RA.

Nat Commun. 2018 Dec 7;9(1):5233. doi: 10.1038/s41467-018-07705-w.

4.

Cysteine Protease-Mediated Autocleavage of Clostridium difficile Toxins Regulates Their Proinflammatory Activity.

Zhang Y, Li S, Yang Z, Shi L, Yu H, Salerno-Goncalves R, Saint Fleur A, Feng H.

Cell Mol Gastroenterol Hepatol. 2018 Feb 9;5(4):611-625. doi: 10.1016/j.jcmgh.2018.01.022. eCollection 2018.

5.

TPL2 Is a Key Regulator of Intestinal Inflammation in Clostridium difficile Infection.

Wang Y, Wang S, Kelly CP, Feng H, Greenberg A, Sun X.

Infect Immun. 2018 Jul 23;86(8). pii: e00095-18. doi: 10.1128/IAI.00095-18. Print 2018 Aug.

6.

Mice with Inflammatory Bowel Disease are Susceptible to Clostridium difficile Infection With Severe Disease Outcomes.

Zhou F, Hamza T, Fleur AS, Zhang Y, Yu H, Chen K, Heath JE, Chen Y, Huang H, Feng H.

Inflamm Bowel Dis. 2018 Feb 15;24(3):573-582. doi: 10.1093/ibd/izx059.

7.

The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.

Zhang Y, Yang Z, Gao S, Hamza T, Yfantis HG, Lipsky M, Feng H.

Anaerobe. 2017 Dec;48:249-256. doi: 10.1016/j.anaerobe.2017.10.006. Epub 2017 Oct 12.

8.
9.

Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity.

Yu H, Chen K, Sun Y, Carter M, Garey KW, Savidge TC, Devaraj S, Tessier ME, von Rosenvinge EC, Kelly CP, Pasetti MF, Feng H.

Clin Vaccine Immunol. 2017 Aug 4;24(8). pii: e00037-17. doi: 10.1128/CVI.00037-17. Print 2017 Aug.

10.
11.

Newly identified bacteriolytic enzymes that target a wide range of clinical isolates of Clostridium difficile.

Mehta KK, Paskaleva EE, Wu X, Grover N, Mundra RV, Chen K, Zhang Y, Yang Z, Feng H, Dordick JS, Kane RS.

Biotechnol Bioeng. 2016 Dec;113(12):2568-2576. doi: 10.1002/bit.26029. Epub 2016 Jun 20.

12.

Identification of an Essential Region for Translocation of Clostridium difficile Toxin B.

Chen S, Wang H, Gu H, Sun C, Li S, Feng H, Wang J.

Toxins (Basel). 2016 Aug 15;8(8). pii: E241. doi: 10.3390/toxins8080241. Erratum in: Toxins (Basel). 2016 Dec 02;8(12 ):.

13.

Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.

Yang Z, Shi L, Yu H, Zhang Y, Chen K, Saint Fleur A, Bai G, Feng H.

Pathog Dis. 2016 Oct;74(7). pii: ftw078. doi: 10.1093/femspd/ftw078. Epub 2016 Aug 7.

14.

Pilin Vaccination Stimulates Weak Antibody Responses and Provides No Protection in a C57Bl/6 Murine Model of Acute Clostridium difficile Infection.

Maldarelli GA, Matz H, Gao S, Chen K, Hamza T, Yfantis HG, Feng H, Donnenberg MS.

J Vaccines Vaccin. 2016;7(3). pii: 321. Epub 2016 May 27.

15.

Pathogenic effects of glucosyltransferase from Clostridium difficile toxins.

Zhang Y, Feng H.

Pathog Dis. 2016 Jun;74(4):ftw024. doi: 10.1093/femspd/ftw024. Epub 2016 Apr 4. Review.

16.

The Brucella melitensis M5-90 phosphoglucomutase (PGM) mutant is attenuated and confers protection against wild-type challenge in BALB/c mice.

Zhang Y, Li T, Zhang J, Li Z, Zhang Y, Wang Z, Feng H, Wang Y, Chen C, Zhang H.

World J Microbiol Biotechnol. 2016 Apr;32(4):58. doi: 10.1007/s11274-016-2015-6. Epub 2016 Feb 29.

PMID:
26925620
17.

The Complete Genome of Brucella Suis 019 Provides Insights on Cross-Species Infection.

Wang Y, Wang Z, Chen X, Zhang H, Guo F, Zhang K, Feng H, Gu W, Wu C, Ma L, Li T, Chen C, Gao S.

Genes (Basel). 2016 Jan 26;7(2). pii: E7. doi: 10.3390/genes7020007.

18.

Defective mutations within the translocation domain of Clostridium difficile toxin B impair disease pathogenesis.

Hamza T, Zhang Z, Melnyk RA, Feng H.

Pathog Dis. 2016 Feb;74(1):ftv098. doi: 10.1093/femspd/ftv098. Epub 2015 Oct 26.

19.

Glucosyltransferase activity of Clostridium difficile Toxin B is essential for disease pathogenesis.

Yang Z, Zhang Y, Huang T, Feng H.

Gut Microbes. 2015 Jul 4;6(4):221-4. doi: 10.1080/19490976.2015.1062965. Epub 2015 Jun 19.

20.

Identification of toxemia in patients with Clostridium difficile infection.

Yu H, Chen K, Wu J, Yang Z, Shi L, Barlow LL, Aronoff DM, Garey KW, Savidge TC, von Rosenvinge EC, Kelly CP, Feng H.

PLoS One. 2015 Apr 17;10(4):e0124235. doi: 10.1371/journal.pone.0124235. eCollection 2015.

Supplemental Content

Loading ...
Support Center